Biology and Treatment of Chronic Myeloid Leukemia (CML)

The CML research group has a clinical component, which is involved in the design and conduction of national and international clinical studies, and a laboratory component, which performs translational research.

Research area:

Chronic Myeloid Leukemia (CML)

 

Clinical CML Research:

  •  Design and conduction of experimental, clinical studies assessing the effectiveness and safety of tyrosine-kinase inhibitors (imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib) in various lines of therapy;
  • Testing of new drugs and innovative therapeutic strategies aimed at the suspension of treatment;
  • Optimization of second-line therapies in relation to their tolerability and the patient’s risk profile;
  • Analysis of prognostic factors;
  • Evaluation of the quality of life of CML patients;
  • creation of registers or extended observational studies for the investigation of the causes of resistance and of advanced-phase CML.

 

For many years, the Seràgnoli Institute has had a prominent role in the CML Working Party of GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto), having provided decisive contributions in drafting clinical study protocols, obtaining the necessary funds, coordinating the participating centers, conducting the final data analysis, and, finally, presenting and publishing the results. In addition, the center collaborates with many hematological centers within the CML Working Party of the network European LeukemiaNet (ELN) and Outcome Study (EUTOS) for CML, the result of a collaboration between ELN and Novartis Oncology Europe.

The research group organizes scientific events at the national and international levels, takes part in the management of national bodies, and is actively involved in defining national and international guidelines and recommendations on CML. The group also conducts many investigator-initiated or company-sponsored prospective Phase I, II, or III clinical or observational studies, in accordance with ICH-GCP guidelines, as well as some retrospective studies. Further, it is actively involved funded research projects (PRIN, FIRB, AIL, and AIRC).

 

 Translational CML Research:

  •  study of the biology of leukemic stem cells, with particular focus on the pathways that contribute to drug resistance;
  • genomic and functional studies of the mechanisms of disease progression from the chronic phase to the blast phase;
  • optimization of new ‘high throughput’ technologies (NGS, digital PCR) for monitoring the molecular response and the identification of the mutations that confer resistance to treatment with tyrosine-kinase inhibitors.

Principal Investigators

Team

Sara De Santis

PhD Student

Cecilia Monaldi

PhD Student

Simona Soverini

Associate Professor

Collaborators

 Clinical research team:

Fausto Castagnetti, (associate professor, chief physician)

Gabriele Gugliotta, (chief physician)

Miriam Iezza, (graduate student)

Michela Zanfagna, (research assistant)

 

Translational biology research team:

Simona Soverini, (tenured professor)

Emanuela Ottaviani, (chief biologist)

Manuela Mancini,  (contractor)

Sara De Santis,  (graduate student)

Cecilia Monaldi, (graduate student)

Claudia Venturi, (research assistant)

How to reach us

Pavillion 8 - Sant'Orsola